Gambogenic acid induces cell growth inhibition, cell cycle arrest and metastasis inhibition in choroidal melanoma in a dose‑dependent manner

Li,Fenghua; Wang,Yansa; Yan,Ying

doi:10.3892/etm.2017.4252

Gambogenic acid induces cell growth inhibition, cell cycle arrest and metastasis inhibition in choroidal melanoma in a dose‑dependent manner

Authors:
- Fenghua Li
- Yansa Wang
- Ying Yan
View Affiliations

Affiliations: Department of Ophthalmology, Linyi People's Hospital, Linyi, Shandong 276000, P.R. China
Published online on: March 22, 2017 https://doi.org/10.3892/etm.2017.4252
Pages: 2456-2462

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to explore the effects of gambogenic acid (GNA) on the malignant behaviors of choroidal melanoma cells, including cell viability, cell cycle, migration and invasion, and to elucidate the underlying regulatory mechanism. The human choroidal melanoma cell line OCM‑1 was treated with different concentrations of GNA and cell viability, colony formation ability, cell cycle, migration and invasion were analyzed. Additionally, cells were incubated with or without LY294002, a specific inhibitor of the phosphoinositide 3‑kinase (PI3K)/protein kinase B (Akt) signaling pathway, for 24 h. Levels of cell cycle‑associated proteins (cyclin D1, cyclin E, cyclin‑dependent kinase 2 and P21), epithelial‑mesenchymal transition (EMT)‑associated molecules (epithelial‑cadherin, α‑smooth muscle actin and vimentin) and phosphorylated (p)‑AKT/AKT were determined using reverse transcription‑quantitative polymerase chain reaction and western blot analysis. The results demonstrated that GNA significantly inhibited cell viability and induced cell cycle arrest at the G0/G1 phase in a dose‑dependent manner (P<0.01). Furthermore, GNA administration significantly suppressed cell migration and invasion in a dose‑dependent manner (P<0.01). Treatment with GNA or LY294002 induced a marked decrease in the expression of p‑AKT/AKT, a significant downregulation in cell cycle‑associated molecules (P<0.01), and a significant decrease in cell viability (P<0.01). Co‑treatment with LY294002 and GNA had an additive effect on the growth of OCM‑1 cells. In conclusion, the results of the present study suggest that treatment with GNA may inhibit cell viability and induce G0/G1 arrest. Furthermore, GNA may also inhibit cell metastasis via regulating EMT‑associated molecules. The PI3K/Akt signaling pathway may be a key mechanism involved in the progression of choroidal melanoma, and GNA may serve as a potential therapeutic reagent for the treatment of this disease.

View Figures

View References

1	Shukla S, Acharya S and Dulani M: Choroid melanoma-A rare case report. J Clin Diagn Res. 9:ED09–ED10. 2015.
2	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
3	Damato B, Eleuteri A, Taktak AF and Coupland SE: Estimating prognosis for survival after treatment of choroidal melanoma. Prog Retin Eye Res. 30:285–295. 2011. View Article : Google Scholar : PubMed/NCBI
4	Aubin JM, Rekman J, Vandenbroucke-Menu F, Lapointe R, Fairfull-Smith RJ, Mimeault R, Balaa FK and Martel G: Systematic review and meta-analysis of liver resection for metastatic melanoma. Br J Surg. 100:1138–1147. 2013. View Article : Google Scholar : PubMed/NCBI
5	Asadi S, Vaez-Zadeh M, Masoudi SF, Rahmani F, Knaup C and Meigooni AS: Gold nanoparticle-based brachytherapy enhancement in choroidal melanoma using a full Monte Carlo model of the human eye. J Appl Clin Med Phys. 16:55682015. View Article : Google Scholar : PubMed/NCBI
6	Yan F, Wang M, Li J, Cheng H, Su J, Wang X, Wu H, Xia L, Li X, Chang HC and Li Q: Gambogenic acid induced mitochondrial-dependent apoptosis and referred to phospho-Erk1/2 and phospho-p38 MAPK in human hepatoma HepG2 cells. Environ Toxicol Pharmacol. 33:181–190. 2012. View Article : Google Scholar : PubMed/NCBI
7	Lu GB, Yang XX and Huang QS: Isolation and structure of neo-gambogic acid from Gamboge (Garcinia hanburryi). Yao Xue Xue Bao. 19:636–639. 1984.In Chinese. PubMed/NCBI
8	Wang X and Chen W: Gambogic acid is a novel anti-cancer agent that inhibits cell proliferation, angiogenesis and metastasis. Anticancer Agents Med Chem. 12:994–1000. 2012. View Article : Google Scholar : PubMed/NCBI
9	Qu BX: The experimental studies on antineoplastic action of gambogic II. Chinese J Clin Oncol. 1:0211991.
10	Li Q, Cheng H, Zhu G, Yang L, Zhou A, Wang X, Fang N, Xia L, Su J, Wang M, et al: Gambogenic acid inhibits proliferation of A549 cells through apoptosis-inducing and cell cycle arresting. Biol Pharm Bull. 33:415–420. 2010. View Article : Google Scholar : PubMed/NCBI
11	Yu XJ, Han QB, Wen ZS, Ma L, Gao J and Zhou GB: Gambogenic acid induces G1 arrest via GSK3β-dependent cyclin D1 degradation and triggers autophagy in lung cancer cells. Cancer Lett. 322:185–194. 2012. View Article : Google Scholar : PubMed/NCBI
12	Chen HB, Zhou LZ, Mei L, Shi XJ, Wang XS, Li QL and Huang L: Gambogenic acid-induced time- and dose-dependent growth inhibition and apoptosis involving Akt pathway inactivation in U251 glioblastoma cells. J Nat Med. 66:62–69. 2012. View Article : Google Scholar : PubMed/NCBI
13	Zhang X, Wang M, Cheng H, Su JJ and Li QL: Effect of gambogenic acid on apoptosis of melanoma cell line B16. J Anhui Traditional Chinese Med College. 1:0202013. View Article : Google Scholar
14	Nogami H, Hiraoka Y and Aiso S: Estradiol and corticosterone stimulate the proliferation of a GH cell line, MtT/S: Proliferation of growth hormone cells. Growth Horm IGF Res. 29:33–38. 2016. View Article : Google Scholar : PubMed/NCBI
15	Luo J, Manning BD and Cantley LC: Targeting the PI3K-Akt pathway in human cancer: Rationale and promise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 4:988–1004. 2005. View Article : Google Scholar : PubMed/NCBI
18	Lejeune FJ, Rimoldi D and Speiser D: New approaches in metastatic melanoma: Biological and molecular targeted therapies. Expert Rev Anticancer Ther. 7:701–713. 2007. View Article : Google Scholar : PubMed/NCBI
19	Robertson GP: Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev. 24:273–285. 2005. View Article : Google Scholar : PubMed/NCBI
20	Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA and McCubrey JA: Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: A target for cancer chemotherapy. Leukemia. 17:590–603. 2003. View Article : Google Scholar : PubMed/NCBI
21	Fatrai S, Elghazi L, Balcazar N, Cras-Méneur C, Krits I, Kiyokawa H and Bernal-Mizrachi E: Akt induces beta-cell proliferation by regulating cyclin D1, cyclin D2, and p21 levels and cyclin-dependent kinase-4 activity. Diabetes. 55:318–325. 2006. View Article : Google Scholar : PubMed/NCBI
22	Davies MA: The role of the PI3K-AKT pathway in melanoma. Cancer J. 18:142–147. 2012. View Article : Google Scholar : PubMed/NCBI
23	Yang J and Weinberg RA: Epithelial-mesenchymal transition: At the crossroads of development and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
24	Thompson EW, Newgreen DF and Tarin D: Carcinoma invasion and metastasis: A role for epithelial-mesenchymal transition? Cancer Res. 65:5991–5995. 2005. View Article : Google Scholar : PubMed/NCBI
25	Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A, Saldanha G, Osborne J, Hutchinson P, Tse G, et al: A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell. 24:466–480. 2013. View Article : Google Scholar : PubMed/NCBI
26	Fenouille N, Tichet M, Dufies M, Pottier A, Mogha A, Soo JK, Rocchi S, Mallavialle A, Galibert MD, Khammari A, et al: The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PLoS One. 7:e403782012. View Article : Google Scholar : PubMed/NCBI
27	Canel M, Serrels A, Frame MC and Brunton VG: E-cadherin-integrin crosstalk in cancer invasion and metastasis. Journal of cell science. 126:393–401. 2013. View Article : Google Scholar : PubMed/NCBI
28	Satelli A and Li S: Vimentin in cancer and its potential as a molecular target for cancer therapy. Cellular and Molecular Life Science. 68:3033–3046. 2011. View Article : Google Scholar
29	Li M, Zhang B, Sun B, Wang X, Ban X, Sun T, Liu Z and Zhao X: A novel function for vimentin: The potential biomarker for predicting melanoma hematogenous metastasis. J Exp Clin Cancer Res. 29:1092010. View Article : Google Scholar : PubMed/NCBI